Friday, August 26, 2016 9:45:10 AM
I'll risk putting my head above the parapet.
1. I expect (near) final data from Direct trial. I expect Method B data to be highly impressive. Following that data, I expect formal confirmation of the trial partnerships to be announced. Three different cancer indications, probably all involving Direct. All that to occur in London on 21st. Possibly a strategic partnership with BMS.
2. I doubt that we will receive much new information on L phase 3, other than being informed of a slow event rate, with data still accruing. Which, I will interpret positively in terms of the likely eventual outcome. I'm prepared to be pleasantly surprised however!
If No. 1 happens, it will be a major public affirmation and legitimation of the Direct platform. And possibly the trigger that NW needs to move back in to the market. At the moment, he is disinclined to draw attention to his existing investment, and I don't think he will renew buying yet due to the inevitable brickbats that will come his way ('throwing good money after bad') from UK commentators, particularly Murdoch organs such as the Times, and from his own investors. On the back of positive conference announcements, however, I think he is highly likely to step back in. After all, he is just another long-suffering long, who believes in the science and its potential, like many on this board. The difference is that due to his high public profile, he has to time a return to the market carefully, and he is also aware of his market-moving impact.
I'm contemplating a modest increase in my holding just before the conferences, in expectation of good things. Hell, if we get no good news, it's not going to reverse much anyway.
Purely my own view and perspective!
Recent NWBO News
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/26/2025 05:15:34 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/31/2025 09:23:24 PM
Exxe Group Advances Platform Strategy and Share Structure Reduction Following Strategic Meetings • AXXA • Mar 11, 2026 1:03 PM
DRCR Pushes Forward With Implementation of 2026 Business Plan • DRCR • Mar 11, 2026 12:26 PM
Record Gold Prices Reshape Opportunities for Emerging Producers • LFLR • Mar 11, 2026 9:00 AM
C2 Blockchain Reports 803 Million DOG (Bitcoin) Holdings Following Strategic Accumulation of Bitcoin-Native Digital Assets • CBLO • Mar 10, 2026 8:00 AM
RENI Completes Due Diligence on Target Acquisition; Confirms Strong Asset Base and Operational Performance • RENI • Mar 5, 2026 10:15 AM
BlackStar Engages in Talks with U.S. Senate Banking Committee Team Covering the Digital Asset Market Clarity Act • BEGI • Mar 4, 2026 4:47 PM
